Navigation Links
Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Date:5/7/2009

-- Management to host call and webcast today at 5:00 p.m. Eastern to discuss financial results and recent business highlights --

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended March 31, 2009.

Three Months Ended March 31, 2009

As of March 31, 2009, Orexigen held $19.8 million in cash and cash equivalents and an additional $44.9 million in investment securities, available-for-sale.

For the three months ended March 31, 2009, Orexigen reported a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, as compared to a net loss of $23.2 million, or $0.73 per share attributable to common stockholders, for the comparable period in 2008.

Total operating expenses for the three months ended March 31, 2009 were $19.1 million compared to $24.0 million for the comparable period in 2008. The decreased operating expenses were due primarily to a decrease of $5.9 million in research and development expenses in connection with the Company's Contrave(R) Phase 3 clinical trials, related proprietary product formulation work and consulting activities, partially offset by an increase in salaries and personnel related costs. In addition, general and administrative expenses increased approximately $46,000 due primarily to an increase in salaries and personnel related costs.

"This is a momentous time for Orexigen," said Michael Narachi, President and CEO. "We are collecting the last of our patient data for the Contrave Phase 3 development program. We believe that if the data is positive, Contrave should have the ability to address a tremendously underserved obesity market. W
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
2. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
3. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
4. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
8. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
9. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
10. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
11. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 The healthcare landscape is rapidly ... Frost & Sullivan will host its 20 th ... , March 8 to 10, at the Hilton San Diego ... This event is a platform for global ... discuss industry disruptions and how to succeed in an uncertain ...
(Date:2/26/2015)... Schaumburg, IL (PRWEB) February 26, 2015 ... to its gauging line by expanding its Length Gauge ... and ACANTO gauges. , Specifically, HEIDENHAIN’s pencil ... an improved force specification. Two new 1Vpp, 12mm ... for lower force applications. One is a variant with ...
(Date:2/26/2015)... February 26, 2015 According to a ... Biotechnology Market For Transgenic Crops (Corn, Soybean, Cotton and ... Analysis, Size, Share, Growth, Trends and Forecast, 2013 – ... 15,300 million in 2012 and is expected to reach ... of 9.5% from 2013 to 2019. , Demand ...
(Date:2/26/2015)... 2015 Ceres, Inc . today announced ... PartnerNetwork. In attaining Gold Level membership, Ceres has been ... knowledge in delivering Ceres, Persephone genome visualization software and ... Originally developed for in-house use by Ceres, the ... out of massive amounts of genetic data, from a ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... 27 Luminex Corporation,(Nasdaq: LMNX ) today ... Organization Investor Forum to be held October 9-11,2007, ... Patrick J. Balthrop, president and chief,executive officer, and ... 9:30 a.m. Pacific time; 12:30 p.m. Eastern time ...
... ... Patients -, BRIDGEWATER and PRINCETON, ... (NYSE: BMY ) announced today that the U.S. Food and Drug,Administration ... of the antiplatelet PLAVIX(R) (clopidogrel,bisulfate). The PLAVIX 300mg tablet will facilitate the ...
... (NYSE: VAR ) and one of Europe,s ... (image guided radiotherapy),training school, enabling hospitals across Europe ... precise radiotherapy technologies available to radiation,oncologists. Clatterbridge ... venue for,the first event of its kind, taking ...
Cached Biology Technology:Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum 2FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 2FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 4FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 5First European IGRT School Takes Place for Radiotherapy Practitioners in UK 2First European IGRT School Takes Place for Radiotherapy Practitioners in UK 3
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
(Date:1/22/2015)... the leading source of biometrics industry news, interviews and thought ... "When we launched FindBiometrics 12 years ago the industry ... and CEO of FindBiometrics. "Now it,s maturing very quickly. More ... on a very broad scale.  We are known for providing ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... the sea turtles could stand up to just about anything ... a hundred million years, they have. But tough, long-lived critters ... Pacific Ocean has plummeted by over 90 percent in the ... a vast ocean, pinpointing all the possible causes of their ...
... WEST LAFAYETTE, Ind. - According to a new ... in snowmelt in the western United States than ... creating new water management challenges for agriculture, ecosystems ... University professor of earth and atmospheric sciences, discovered ...
... a tiny clock called a telomere, which shortens each ... a range of human diseases, including HIV, osteoporosis, heart ... within the cell, called telomerase, keeps immune cells young ... dividing. FINDINGS: , UCLA scientists found that the ...
Cached Biology News:Leatherback turtles' newly discovered migration route may be roadmap to salvation 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 3Leatherback turtles' newly discovered migration route may be roadmap to salvation 4Leatherback turtles' newly discovered migration route may be roadmap to salvation 5Leatherback turtles' newly discovered migration route may be roadmap to salvation 6Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves 2Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves 3
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Request Info...
Biology Products: